EXEL vs. ILMN: Exelixis vs. Illumina Stock Comparison

Company Profile

Exelixis (EXEL) and Illumina (ILMN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while ILMN is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Illumina (ILMN) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while Exelixis (EXEL) is defensive at 0.41 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Exelixis (EXEL) at 44.32% and Illumina (ILMN) at 32.39% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Exelixis (EXEL) at 35.45% and Illumina (ILMN) at 19.72% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Exelixis (EXEL) at 40.75% and Illumina (ILMN) at 20.02% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Exelixis (EXEL) at 6.98% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Exelixis (EXEL) reports EPS growth of 57.95%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Exelixis (EXEL) at 3.21 and Illumina (ILMN) at 2.63 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Exelixis (EXEL) at 0.09 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Exelixis (EXEL) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Exelixis (EXEL) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both Exelixis (EXEL) at 20.83 and Illumina (ILMN) at 36.68 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

On P/S ratio, both Exelixis (EXEL) at 6.80 and Illumina (ILMN) at 7.10 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both Exelixis (EXEL) at 9.28 and Illumina (ILMN) at 10.30 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics